Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Cut by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 96.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 847 shares of the biopharmaceutical company's stock after selling 22,744 shares during the quarter. Jacobs Levy Equity Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $603,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in REGN. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after buying an additional 1,390,534 shares during the last quarter. Norges Bank bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $802,036,000. Price T Rowe Associates Inc. MD lifted its stake in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after buying an additional 810,144 shares during the last quarter. Amundi lifted its stake in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after buying an additional 487,489 shares during the last quarter. Finally, Loomis Sayles & Co. L P raised its stake in shares of Regeneron Pharmaceuticals by 33.4% during the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of REGN opened at $594.32 on Friday. The business's 50-day moving average price is $599.96 and its 200 day moving average price is $682.98. The stock has a market capitalization of $64.17 billion, a P/E ratio of 15.53, a P/E/G ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $9.55 EPS. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of recent analyst reports. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. The Goldman Sachs Group cut their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Finally, Bernstein Bank cut their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $890.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.